GAD65 autoantibody epitopes in adult patients with latent autoimmune diabetes following GAD65 vaccination

Diabetic Medicine

Volumn 24, Issue 5, 2007, Pages 521-526

  Bekris, L M ^a   Jensen, R A ^a   Lagerquist, E ^a   Hall, T R ^a   Agardh, C D ^b   Cilio, C M ^b   Lethagen, A L ^b   Lernmark, A ^a,b   Robertson, J A ^c   Hampe, C S ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

^b LUND UNIVERSITY HOSPITAL   (Sweden)

^c KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Autoimmunity; Therapy; Type 1 diabetes

Indexed keywords

AUTOANTIBODY; EPITOPE; GLUTAMATE DECARBOXYLASE 65; GLUTAMATE DECARBOXYLASE 65 ANTIBODY; GLUTAMATE DECARBOXYLASE 67; HYBRID PROTEIN; IMMUNOGLOBULIN F(AB) FRAGMENT; PLACEBO;

ADULT; AGED; ARTICLE; AUTOIMMUNE DISEASE; BLOOD SAMPLING; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETES MELLITUS; DRUG FORMULATION; FEMALE; HUMAN; IMMUNE RESPONSE; MALE; RANDOMIZED CONTROLLED TRIAL; VACCINATION;

ADULT; AGED; AUTOANTIBODIES; AUTOIMMUNE DISEASES; DIABETES MELLITUS, TYPE 1; EPITOPES; FEMALE; GLUTAMATE DECARBOXYLASE; HUMANS; MALE; MIDDLE AGED; VACCINATION;

EID: 34247574292     PISSN: 07423071     EISSN: 14645491     Source Type: Journal    
DOI: 10.1111/j.1464-5491.2007.02091.x     Document Type: Article

References (42)

1. Gepts W. Pathologic anatomy of the pancreas in juvenile diabetes mellitus. Diabetes 1965 14 : 619 633.
2. Baekkeskov S, Aanstoot HJ, Christgau S, Reetz A, Solimena M, Cascalho M. Identification of the 64K autoantigen in insulin-dependent diabetes as the GABA-synthesizing enzyme glutamic acid decarboxylase. Nature 1990 347 : 151 156.
3. Karlsen AE, Hagopian WA, Grubin CE, Dube S, Disteche CM, Adler DA. Cloning and primary structure of a human islet isoform of glutamic acid decarboxylase from chromosome 10. Proc Natl Acad Sci USA 1991 88 : 8337 8341.
4. Palmer JP. Predicting IDDM - the use of humoral immune markers. Diabetes Rev 1993 1 : 104 115.
5. Lan MS, Lu J, Goto Y, Notkins AL. Molecular cloning and identification of a receptor-type protein tyrosine phosphatase, IA-2, from human insulinoma. DNA Cell Biol 1994 13 : 505 514.
6. Rabin DU, Pleasic SM, Palmer-Crocker R, Shapiro JA. Cloning and expression of IDDM-specific human autoantigens. Diabetes 1992 41 : 183 186.
7. Leslie D, Lipsky P, Notkins AL. Autoantibodies as predictors of disease. J Clin Invest 2001 108 : 1417 1422.
8. Falorni A, Brozzetti A. Diabetes-related antibodies in adult diabetic patients. Best Pract Res Clin Endocrinol Metab 2005 19 : 119 133.
9. Verge CF, Gianani R, Kawasaki E, Yu L, Pietropaolo M, Jackson RA. Prediction of type I diabetes in first-degree relatives using a combination of insulin, GAD, and ICA512bdc/IA-2 autoantibodies. Diabetes 1996 45 : 926 933.
10. Bingley PJ, Christie MR, Bonifacio E, Bonfanti R, Shattock M, Fonte MT. Combined analysis of autoantibodies improves prediction of IDDM in islet cell antibody-positive relatives. Diabetes 1994 43 : 1304 1310.
11. Zimmet PZ, Tuomi T, Mackay IR, Rowley MJ, Knowles W, Cohen M. Latent autoimmune diabetes mellitus in adults (LADA): the role of antibodies to glutamic acid decarboxylase in diagnosis and prediction of insulin dependency. Diabet Med 1994 11 : 299 303.
12. Harris MI, Zimmet P. Classification of diabetes mellitus and other catagories of glucose intolerance. In : Keen, H, DeFronzo, R, Alberti, K, Zimmet, P, eds. The International Textbook of Diabetes Mellitus. London : Wiley, 1992 : 3 18.
13. Kobayashi T, Tamemoto K, Nakanishi K, Kato N, Okubo M, Kajio H. Immunogenetic and clinical characterization of slowly progressive IDDM. Diabetes Care 1993 16 : 780 788.
14. Pietropaolo M, Barinas-Mitchell E, Pietropaolo SL, Kuller LH, Trucco M. Evidence of islet cell autoimmunity in elderly patients with type 2 diabetes. Diabetes 2000 49 : 32 38.
15. Gambelunghe G, Forini F, Laureti S, Murdolo G, Toraldo G, Santeusanio F. Increased risk for endocrine autoimmunity in Italian type 2 diabetic patients with GAD65 autoantibodies. Clin Endocrinol (Oxf) 2000 52 : 565 573.
16. Temple RC, Carrington CA, Luzio SD, Owens DR, Schneider AE, Sobey WJ. Insulin deficiency in non-insulin-dependent diabetes. Lancet 1989 1 : 293 295.
17. Gjessing HJ, Matzen LE, Faber OK, Froland A. Fasting plasma C-peptide, glucagon stimulated plasma C-peptide, and urinary C-peptide in relation to clinical type of diabetes. Diabetologia 1989 32 : 305 311.
18. Groop LC, Bottazzo GF, Doniac D. Islet cell antibodies identify latent type 1 diabetes in patients aged 35-75 years at diagnosis. Diabetes 1986 35 : 237 241.
19. Rowley MJ, Mackay IR, Chen QY, Knowles WJ, Zimmet PZ. Antibodies to glutamic acid decarboxylase discriminate major types of diabetes mellitus. Diabetes 1992 41 : 548 551.
20. Tuomi T, Groop LC, Zimmet PZ, Rowley MJ, Knowles W, Mackay IR. Antibodies to glutamic acid decarboxylase reveal latent autoimmune diabetes mellitus in adults with a non-insulin-dependent onset of disease. Diabetes 1993 42 : 359 362.
21. Turner R, Stratton I, Horton V, Manley S, Zimmet P, Mackay IR. UKPDS 25: autoantibodies to islet-cell cytoplasm and glutamic acid decarboxylase for prediction of insulin requirement in type 2 diabetes. UK Prospective Diabetes Study Group. Lancet 1997 350 : 1288 1293.
22. Ramiya VK, Lan MS, Wasserfall CH, Notkins AL, Maclaren NK. Immunization therapies in the prevention of diabetes. J Autoimmun 1997 10 : 287 292.
23. Jun H-S, Chung Y-H, Han J, Kim A, Yoo SS, Sherwin RS. Prevention of autoimmune diabetes by immunogene therapy using recombinant vaccinia virus expressing glutamic acid decarboxylase. Diabetologia 2002 45 : 668 676.
24. Petersen JS, Karlsen AE, Markholst H, Worsaae A, Dyrberg T, Michelsen B. Neonatal tolerization with glutamic acid decarboxylase but not with bovine serum albumin delays the onset of diabetes in NOD mice. Diabetes 1994 43 : 1478 1484.
25. Tisch R, Yang XD, Liblau RS, McDevitt HO. Administering glutamic acid decarboxylase to NOD mice prevents diabetes. J Autoimmun 1994 7 : 845 850.
26. Tisch R, Liblau RS, Yang XD, Liblau P, McDevitt HO. Induction of GAD65-specific regulatory T-cells inhibits ongoing autoimmune diabetes in non-obese diabetic mice. Diabetes 1998 47 : 894 899.
27. Tisch R, Wang B, Serreze DV. Induction of glutamic acid decarboxylase 65-specific Th2 cells and suppression of autoimmune diabetes at late stages of disease is epitope dependent. J Immunol 1999 163 : 1178 1187.
28. Agardh CD, Cilio CM, Lethagen A, Lynch K, Leslie RD, Palmer M. Clinical evidence for the safety of GAD65 immunomodulation in adult-onset autoimmune diabetes. J Diabetes Complications 2005 19 : 238 246.
29. Grubin C, Daniels T, Karlsen AE, Boel E, Hagopian WA, Lernmark Å. The cDNA-directed, in vitro-synthesized nascent peptide of glutamic acid decarboxylase (GAD2) is the autoantigen in insulin-dependent diabetes. Clin Res 1992 40 : 299A.
30. Mire-Sluis AR, Das RG, Lernmark Å. The World Health Organization International Collaborative Study for Islet Cell Antibodies. Diabetologia 2000 43 : 1282 1292.
31. Grubin CE, Daniels T, Toivola B, Landin-Olsson M, Hagopian WA, Li L. A novel radioligand binding assay to determine diagnostic accuracy of isoform-specific glutamic acid decarboxylase antibodies in childhood IDDM. Diabetologia 1994 37 : 344 350.
32. Madec AM, Rousset F, Ho S, Robert F, Thivolet C, Orgiazzi J. Four IgG anti-islet human monoclonal antibodies isolated from a type 1 diabetes patient recognize distinct epitopes of glutamic acid decarboxylase 6 5 and are somatically mutated. J Immunol 1996 156 : 3541 3549.
33. Jaume JC, Parry SL, Madec AM, Sonderstrup G, Baekkeskov S. Suppressive effect of glutamic acid decarboxylase 65-specific autoimmune B lymphocytes on processing of T cell determinants located within the antibody epitope. J Immunol 2002 169 : 665 672.
34. Schwartz HL, Chandonia JM, Kash SF, Kanaani J, Tunnell E, Domingo A. High-resolution autoreactive epitope mapping and structural modeling of the 65-kDa form of human glutamic acid decarboxylase. J Mol Biol 1999 287 : 983 999.
35. Tremble J, Morgenthaler NG, Vlug A, Powers AC, Christie MR, Scherbaum W. Human B cells secreting immunoglobulin G to glutamic acid decarboxylase-65 from a non-diabetic patient with multiple autoantibodies and Graves' disease: a comparison with those present in type 1 diabetes. J Clin Endocrinol Metab 1997 82 : 2664 2670.
36. Padoa CJ, Banga JP, Madec AM, Ziegler M, Schlosser M, Ortqvist E. Recombinant Fabs of human monoclonal antibodies specific to the middle epitope of GAD65 inhibit type 1 diabetes-specific GAD65Abs. Diabetes 2003 52 : 2689 2695.
37. Carter P, Kelley RF, Rodrigues ML, Snedecor B, Covarrubias M, Velligan MD. High level Escherichia coli expression and production of a bivalent humanized antibody fragment. Biotechnology (N Y) 1992 10 : 163 167.
38. Neidhardt FC, Bloch PL, Smith DF. Culture medium for enterobacteria. J Bacteriol 1974 119 : 736 747.
39. Hampe CS, Ortqvist E, Rolandsson O, Landin-Olsson M, Torn C, Agren A. Species-specific autoantibodies in type 1 diabetes. J Clin Endocrinol Metab 1999 84 : 643 648.
40. Binder KA, Banga JP, Madec AM, Ortqvist E, Luo D, Hampe CS. Epitope analysis of GAD65Ab using fusion proteins and rFab. J Immunol Meth 2004 295 : 101 109.
41. Schlosser M, Banga JP, Madec AM, Binder KA, Strebelow M, Rjasanowski I. Dynamic changes of GAD65 autoantibody epitope specificities in individuals at risk of developing type 1 diabetes. Diabetologia 2005 48 : 922 930.
42. Gilliam LK, Binder KA, Banga JP, Madec AM, Ortqvist E, Kockum I et al. Multiplicity of the antibody response to GAD65 in Type I diabetes. Clin Exp Immunol 2004 138 : 337 341.